Brain & sleep Anxiolytic peptide (Russian)
Selank
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- FDA approval
- Not FDA-approved for any use
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
Selank is a synthetic anxiolytic peptide developed in Russia, where it is approved for anxiety, and sold elsewhere on the "research peptide" market for anxiety and focus. The human evidence is limited to small, mostly Russian-language studies that have not been independently replicated to Western regulatory standards. As of 2026 it is not FDA-approved.
At a glance
- FDA status
- Not FDA-approved, sold in the wellness/gray market, and approved in Russia
- What it is
- Synthetic peptide based on the natural immune-modulating peptide tuftsin
- Research
- Human evidence limited to small, mostly developer-affiliated Russian studies
- How it's taken
- Typically used intranasally where it is marketed
- Evidence strength
- Low research
Summary
Selank is a synthetic peptide approved for anxiety in Russia but not by the FDA. Learn how it is proposed to work and how limited the human evidence is.
What is selank?
Selank, sometimes shorthanded as TP-7, is a synthetic seven-amino acid peptide, a stabilized analog of a natural peptide called tuftsin. It was developed by Russian research institutes and is approved in Russia as an anti-anxiety agent. Outside Russia it is sold through wellness and "research peptide" channels for anxiety and focus, and it is not an approved medicine in the United States.
How does it work?
Selank is proposed to have calming effects by modulating the brain's enkephalin and GABA systems, influencing serotonin metabolism, and affecting levels of a nerve-growth signal called BDNF. These mechanisms come mainly from animal and laboratory work. This describes the proposed mechanism, separate from demonstrated benefit in people.
Is it FDA-approved?
Safety note
Status: Not FDA-approved, sold in the wellness/gray market, and approved in Russia
Category: Wellness and performance · Primary body area: Brain & sleep
No. Selank is not approved by the FDA. It is approved as an anxiolytic in Russia. In the United States it is sold only as a "research chemical," is not on FDA compounding lists, and was not among the peptides reviewed favorably at the 2026 FDA compounding advisory meetings.
What does the research show?
Editor’s note
Evidence strength: Low research
Human data exist but are limited to small, non-independent, largely developer-affiliated studies without regulatory-grade replication.
There is some human evidence, but of limited quality. Small Russian studies have reported anxiety-reducing effects, including a comparison with a benzodiazepine and a study suggesting selank reduced benzodiazepine side effects. These trials are generally:
- Small
- Single-country
- Often conducted by the developing institutions
- Published in Russian
- Not independently replicated
An analytical review notes that such peptides have not completed clinical trials to Western regulatory standards. The evidence does not establish efficacy by those standards.
What is the difference between selank and semax?
Selank and semax are both synthetic seven-amino acid peptides developed by Russian research institutes, and the main difference is the natural molecule each is based on and the use each is approved for in Russia. Their proposed mechanisms are also described differently.
| Attribute | Selank | Semax |
|---|---|---|
| Based on | Tuftsin, a natural immune-modulating peptide (selank is a stabilized analog) | A fragment of the hormone ACTH |
| Approved in Russia for | Anti-anxiety agent | Stroke and cognitive and neurological conditions |
| Proposed mechanism | Acts on the brain's enkephalin and GABA systems and on serotonin metabolism | Raises nerve-growth signals such as BDNF and NGF |
| FDA status | Not FDA-approved | Not FDA-approved |
| FDA compounding advisory review | Not among the peptides reviewed favorably | Non-binding favorable vote in July 2026 toward allowing it to be compounded, which FDA staff opposed |
Both mechanism descriptions come mainly from animal and laboratory work, and neither has been shown to produce a benefit in people. The advisory vote is the one U.S. regulatory difference, and an advisory vote is only a recommendation; it does not make semax approved.
The human evidence for both is limited in the same way: small, mostly Russian studies, often run by the developing institutions and not independently replicated. An analytical review notes that such peptides have not completed clinical trials to Western regulatory standards. The evidence does not establish that either one works or that one works better than the other.
Sources: a Russian clinical study of selank (Medvedev et al., Zhurnal Nevrologii i Psikhiatrii, 2015, DOI: 10.17116/jnevro20151156133-40) and an analytical review of research peptides (Esposito et al., Drug Testing and Analysis, 2020, DOI: 10.1002/dta.2717), indexed on PubMed. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
Compare every peptide’s status in the peptide regulatory status database
More for Brain & sleep
View all brain & sleep peptides →- FDA-approved Brain & sleep
Bremelanotide
Bremelanotide is a synthetic seven-amino acid peptide that activates melanocortin receptors in the brain to increase sexual desire, unlike blood-flow drugs such as sildenafil. In the two RECONNECT phase 3 trials of 1,267 premenopausal women with hypoactive sexual desire disorder (HSDD), it raised the desire score 0.35 points more than placebo and reduced desire-related distress 0.33 points more (both P<.001) over 24 weeks. It is FDA-approved as Vyleesi, a prescription self-injection for acquired, generalized HSDD. Versions sold online as PT-141 are not the FDA-approved product and are not quality-controlled.
- Not FDA-approved Brain & sleep
Cerebrolysin
Cerebrolysin is a preparation of small peptides and amino acids derived from pig brain, used in some countries for stroke and dementia and sold elsewhere for cognition. It has been tested in many human trials, but systematic reviews found no clear benefit on survival or function after stroke and only a weak, low-quality signal in vascular dementia. As of 2026 it is not FDA-approved in the United States.
- In clinical trials Brain & sleep
Davunetide
Davunetide is an investigational neuroprotective peptide derived from a brain protein, studied as an intranasal treatment for the rare neurodegenerative disease progressive supranuclear palsy. Its large pivotal trial clearly failed, showing no benefit over placebo, and earlier signals in other conditions were small and never confirmed. As of 2026 it is not approved.
- Not FDA-approved Brain & sleep
Dihexa
the Research Peptide
Dihexa is an experimental cognition peptide derived from angiotensin IV, sold on the "research peptide" market for brain function. Its evidence is entirely preclinical, with no human trials, and a key paper describing its proposed mechanism has been retracted. As of 2026 it is not FDA-approved or approved anywhere.
- Not FDA-approved Brain & sleep
Dsip
Delta Sleep-Inducing Peptide
DSIP (delta sleep-inducing peptide) is a naturally occurring peptide sold on the "research peptide" market for sleep and stress. Its human evidence is limited to a few small, dated, inconsistent studies, and no validated mechanism or reproducible benefit has been established. As of 2026 it is not FDA-approved and not approved as a drug anywhere.
- Not FDA-approved Brain & sleep
Epitalon
Epitalon is a synthetic four-amino acid peptide based on a pineal-gland extract, sold on the "research peptide" market for anti-aging and sleep. Its human evidence is limited to older studies from a single Russian research group, not independently replicated. As of 2026 it is not FDA-approved, though a 2026 FDA advisory committee gave a non-binding favorable vote toward allowing it to be compounded.